SAB Biotherapeutics Updates SAB-142 Roadmap and Funding Outlook

An update from SAB Biotherapeutics ( (SABS) ) is now available.

On January 12, 2026, SAB Biotherapeutics posted an updated corporate presentation outlining strong 2025 execution and a multi‑year clinical and financial roadmap centered on SAB‑142 for newly diagnosed Stage 3 Type 1 diabetes. The company reported that its registrational Phase 2b SAFEGUARD trial is expected to begin dosing in late 2025, complete enrollment by the end of 2026, and deliver topline data in the second half of 2027, supported by prior MELD and Phase 1 data indicating efficacy signals and a favorable safety profile without lymphodepletion or immunogenicity on redosing; with $144 million in cash and equivalents as of December 31, 2025 and projected runway through 2028, SAB Biotherapeutics signaled it is well funded to advance SAB‑142 within an expanding, clearly regulated T1D treatment landscape shaped by precedent therapies such as Tzield.

The most recent analyst rating on (SABS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on SAB Biotherapeutics stock, see the SABS Stock Forecast page.

Spark’s Take on SABS Stock

According to Spark, TipRanks’ AI Analyst, SABS is a Neutral.

The score is primarily held down by weak financial performance—sharp revenue contraction, negative gross profit, and sustained cash burn—despite a relatively modest-leverage balance sheet. Technicals are neutral-to-slightly positive (above longer-term averages but soft near-term momentum), while valuation is constrained by losses (negative P/E). Corporate events add modest support from governance improvements but are offset by dilution risk from the expanded ATM facility.

To see Spark’s full report on SABS stock, click here.

More about SAB Biotherapeutics

SAB Biotherapeutics, doing business as SAB BIO, is a clinical-stage biotechnology company focused on developing disease‑modifying therapies for autoimmune disorders, with an initial emphasis on autoimmune Type 1 diabetes (T1D). Its lead product candidate, SAB‑142, is a fully human, multi‑specific anti‑thymocyte globulin designed to modulate T cells and preserve pancreatic function, built on a proprietary Tc Bovine platform that produces targeted, fully human multi‑specific polyclonal antibodies without human donors, positioning the company in a large and growing global T1D market with high barriers to entry and backing from specialist life science investors.

Average Trading Volume: 268,782

Technical Sentiment Signal: Buy

Current Market Cap: $183.8M

Find detailed analytics on SABS stock on TipRanks’ Stock Analysis page.